Trial 10M-17-2


A phase III, open-label, multicenter, two arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab versus pembrolizumab in patients with previously untreated advanced BRAFv600 wild-type melanoma

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Immunotherapy
Randomized: Yes
USC Satellite Location: USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Lusine Raddatz, D.M., Victoria Amran, D.M., Kristy Sartor Massopust, Coordinator, Shamim Jhimlee, Coordinator, Jubilee Acap, Coordinator, Laurie De Oliveira, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.